Day One Biopharmaceuticals (DAWN) Investor Presentation - Slideshow

MR(includes 4 uMR) PD# All 4 patients with uPR and 3 patients with uMR remain on treatment as of May 23, 2023 20 (26%) MAPKi-naive Prior MAPKi therapy BRAF V600E mutation Best Tumor Response (%) -100 -80 -60 -40 -20 0 20 40 60 80 180 100 PD SD PR CR MR SD PD# Best overall response, n (%) CR Dec 22, 2022 data cutoff. Percents may not add to 100% due to rounding. #PD for RANO-LGG was not used to determine treatment discontinuation; patients could continue treatment if there was no PD based on RANO-HGG per inv ...